Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Latigo Biotherapeutics, Inc. (LTGO) received a Schedule 13G reporting that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin together beneficially own 4,445,656 shares of Latigo common stock, representing 7.03% of the outstanding common shares.
The reporting persons have shared voting and dispositive power over these 4,445,656 shares and no sole voting or dispositive power. The ownership percentage is based on 63,238,030 shares of common stock outstanding as of August 7, 2026, as described in Latigo’s prospectus.
Key Figures
Shares beneficially owned:4,445,656 shares of common stockPercent of class:7.03%Shares outstanding:63,238,030 shares of common stock+4 more
7 metrics
Shares beneficially owned4,445,656 shares of common stockBeneficial ownership reported by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin
Percent of class7.03%Ownership percentage of Latigo Biotherapeutics common stock
Shares outstanding63,238,030 shares of common stockCommon stock outstanding as of August 7, 2026, per Latigo prospectus
Shared voting power4,445,656 sharesShares over which the reporting persons have shared power to vote
Sole voting power0 sharesShares over which the reporting persons have sole power to vote
Shared dispositive power4,445,656 sharesShares over which the reporting persons have shared power to dispose
Sole dispositive power0 sharesShares over which the reporting persons have sole power to dispose
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared power to vote or to direct the vote: 4,445,656"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive powerfinancial
"Shared power to dispose or to direct the disposition of: 4,445,656"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
parent holding companyfinancial
"If a parent holding company has filed this schedule, pursuant to (ii)(G)"
control personfinancial
"Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Latigo Biotherapeutics (LTGO) does Deep Track Capital report owning?
Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 7.03% of Latigo Biotherapeutics’ common stock, based on 63,238,030 shares outstanding as of August 7, 2026.
How many LTGO shares are beneficially owned by the Deep Track reporting group?
The reporting persons disclose beneficial ownership of 4,445,656 shares of Latigo Biotherapeutics common stock, with shared voting and shared dispositive power over all of these shares.
What share count did the LTGO Schedule 13G use to calculate ownership percentage?
The Schedule 13G calculates ownership using 63,238,030 shares of Latigo Biotherapeutics common stock outstanding as of August 7, 2026, as stated in the company’s prospectus filed that day.
Do the Deep Track entities have sole or shared voting power over LTGO shares?
They report 0 shares with sole voting power and 4,445,656 shares with shared voting power, matching the number of shares beneficially owned.
Who are the reporting persons on the Latigo Biotherapeutics (LTGO) Schedule 13G?
The reporting persons are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. They filed jointly under a Rule 13d-1(k) joint filing statement.
What dispositive power over LTGO shares is reported by Deep Track and its affiliates?
They report 0 shares with sole dispositive power and 4,445,656 shares with shared dispositive power, indicating joint authority over decisions to dispose of these shares.
(i) Delaware
(ii) Cayman Islands
(iii) United States
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
517954103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4,445,656
(b)
Percent of class:
7.03%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,445,656
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,445,656
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Deep Track Capital, LP
Signature:
/s/ David Kroin
Name/Title:
David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:
08/13/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:
/s/ David Kroin
Name/Title:
David Kroin, Director
Date:
08/13/2026
David Kroin
Signature:
/s/ David Kroin
Name/Title:
David Kroin
Date:
08/13/2026
Exhibit Information
Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of August 13, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.
The amount beneficially owned by each Reporting Person is determined using 63,238,030 shares, calculated
using 63,238,030 Common Stock outstanding as of August 7, 2026, according to the issuer's Prospectus filed with the SEC on August 7, 2026.
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: August 13, 2026
Deep Track Capital, LP
By: /s/ David Kroin
David Kroin, Managing Member of the General Partner of the Investment Adviser
Deep Track Biotechnology Master Fund, Ltd.
By: /s/ David Kroin
David Kroin, Director
David Kroin
By: /s/ David Kroin
David Kroin
